Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Forward Printable StoryPrint Comment




Health IT Homepage

MedInformatix unveils the "State of RIS"

Medivis launches with $2.3 million in funding to transform surgical visualization

Telemedicine promises to advance healthcare in Latin America, but faces systemic obstacles, research from FIU business finds

Hearst Health shares recommendations from healthcare interoperability report at HIMSS19 conference

Carevive awarded National Cancer Institute SBIR fast-track to advance symptom management clinical decision support technology

Griffin Health launches its frameless SRS program using C-RAD Catalyst HD with cBrain software

Novel software offers possible reduction in arrhythmic heart disease

New survey from HIMSS Media and Hyland Healthcare quantifies needs, challenges and goals for interoperable technology

Philips launches latest iteration of IntelliSpace Cardiovascular at HIMSS19

Boehringer Ingelheim (Canada) Ltd. and IBM Canada to integrate blockchain into clinical trials

FDA grants breakthrough device designation for CTEPH pattern recognition AI software from Bayer and Merck

Press releases may be edited for formatting or style
WHIPPANY, N.J. and PITTSBURGH, Dec. 3, 2018 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Artificial Intelligence (AI) Pattern Recognition Software, which Bayer is currently developing jointly with Merck, known as MSD outside the U.S. and Canada.

A rare form of pulmonary hypertension, CTEPH affects an estimated 5 individuals per million per year globally.i CTEPH can be difficult to diagnose because its symptoms are similar to those of other conditions such as asthma or Chronic Obstructive Pulmonary Disease (COPD). i,ii Being a rare disease, physicians may not always recognize CTEPH. Computed Tomography Pulmonary Angiography (CTPA) as well as a ventilation/perfusion scan (V/Q scan) are used to determine if thromboembolic occlusion is causing the pulmonary hypertension. Radiologists may have the first opportunity to identify CTEPH in a patient; therefore it's important they accurately detect CTEPH indicators on CTPA scans and images.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Development of the CTEPH Pattern Recognition AI Software will use deep learning methodology to support radiologists by identifying signs of CTEPH in CTPA scans. This software analyzes image findings from cardiac, lung perfusion and pulmonary vessels in combination with the patient's clinical history. If the development is successful, the software could be deployed via Bayer's Radimetrics software, an informatics technology platform that connects contrast medium, injector and scan information to provide important insights.

"Bayer is looking forward to leveraging our expertise in radiology to develop a software to support radiologists and treating physicians in the complex diagnostic decision making process of this rare disease," said Prof. Dr. Olaf Weber, Head of Radiology Research & Development of Bayer AG's Pharmaceuticals Division. "We hope that greater awareness of CTEPH in conjunction with a decision-support tool will eventually assist in diagnosing patients earlier and more reliably, thereby allowing earlier treatment."

The FDA Breakthrough Device Program is intended to help patients have more timely access to devices and breakthrough technologies that provide for more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases by expediting their development, assessment, and review. While the FDA Breakthrough Device Designation is expected to expedite the software's assessment and review, its development remains complex given the nature of the disease and technology.
  Pages: 1 - 2 - 3 >>

Health IT Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.